U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
RegulatoryapprovedZiiheraTislelizumabPositive
AI Analysis
Summary
The FDA approved Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma, establishing a new standard of care regardless of PD-L1 status.
Outcome Details
FDA approved Ziihera (zanidatamab-hrii) with and without tislelizumab plus chemotherapy for first-line treatment of HER2+ advanced gastroesophageal adenocarcinoma in all patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status
Importance:9/10
Sentiment:
0.95
FDA approvalOncologyGastroesophageal cancerHER2+First-line treatmentCombination therapyStandard of care
Related Companies
Read the original article
Published by PR Newswire Biotech on August 25, 2026 2:00 PM